
<html>
  <head>
    <link href="https://fonts.googleapis.com/css?family=Lato:400,900,700,700italic,400italic,300italic,300,100italic,100,900italic" rel="stylesheet" type="text/css">
    <link href="https://fonts.googleapis.com/css?family=Dosis:400,500,700,800,600,300,200" rel="stylesheet" type="text/css">
    <link rel="stylesheet" type="text/css" href="..\html-styles.css">
  </head>
  <body><h2 id="22dataused">2.2 Data used</h2>
<h3 id="221invitrophysicochemicaldata">2.2.1    In vitro / physico-chemical data</h3>
<p>A literature search was performed to collect available information on physical chemical properties of raltegravir. The obtained information from literature is summarized in the table below, and is used for model building.</p>
<table>
<thead>
<tr>
<th style="text-align:left;"><strong>Parameter</strong></th>
<th><strong>Unit</strong></th>
<th><strong>Raltegravir literature</strong></th>
<th><strong>Description</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">MW</td>
<td>g/mol</td>
<td>586.2 (<a href="./References.md">drugbank.ca</a>)</td>
<td>Molecular weight</td>
</tr>
<tr>
<td style="text-align:left;">pKa</td>
<td></td>
<td>7.67 (<a href="./References.md">Moss 2012</a>)</td>
<td>Acid dissociation constant</td>
</tr>
<tr>
<td style="text-align:left;">Solubility (pH)</td>
<td>mg/L</td>
<td>Reference pH-dependent table  (<a href="./References.md">Moss 2013</a>)</td>
<td>Solubility</td>
</tr>
<tr>
<td style="text-align:left;">logP</td>
<td></td>
<td>0.58 (<a href="./References.md">Moss 2012</a>)</td>
<td>Lipophilicity</td>
</tr>
<tr>
<td style="text-align:left;">fu</td>
<td></td>
<td>0.17 (<a href="./References.md">Laufer 2009</a>)</td>
<td>Fraction unbound</td>
</tr>
<tr>
<td style="text-align:left;">UGT1A1</td>
<td>µM</td>
<td>99 (<a href="./References.md">Kassahun 2007</a>)</td>
<td>Michaelis-Menten constant (Km)</td>
</tr>
<tr>
<td style="text-align:left;">UGT1A1</td>
<td>nmol/min/mg</td>
<td>0.89 (<a href="./References.md">Kassahun 2007</a>)</td>
<td>Vmax</td>
</tr>
<tr>
<td style="text-align:left;">UGT1A9</td>
<td>µM</td>
<td>296 (<a href="./References.md">Kassahun 2007</a>)</td>
<td>Michaelis-Menten constant (Km)</td>
</tr>
<tr>
<td style="text-align:left;">UGT1A9</td>
<td>nmol/min/mg</td>
<td>0.53 (<a href="./References.md">Kassahun 2007</a>)</td>
<td>Vmax</td>
</tr>
</tbody>
</table>
<h3 id="222clinicaldata">2.2.2    Clinical data</h3>
<p>A literature search was performed to collect available clinical data on Raltegravir in adults. </p>
<p>The following publications were found in adults for model building and evaluation:</p>
<table>
<thead>
<tr>
<th style="text-align:left;">Publication</th>
<th style="text-align:left;">Study description</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;"><a href="./References.md">Iwamoto 2008</a></td>
<td style="text-align:left;">Single- and multiple-dose escalation study in healthy subjects</td>
</tr>
<tr>
<td style="text-align:left;"><a href="./References.md">Iwamoto 2009</a></td>
<td style="text-align:left;">Effects of ritonavir and efavirenz on safety, tolerability and pharmacokinetics of raltegravir</td>
</tr>
<tr>
<td style="text-align:left;"><a href="./References.md">Markowitz 2006</a></td>
<td style="text-align:left;">Monotherapy, followed by a longer term combination therapy of raltegravir versus efavirenz</td>
</tr>
<tr>
<td style="text-align:left;"><a href="./References.md">Kassahun 2007</a></td>
<td style="text-align:left;">Pharmacokinetics study in healthy adults</td>
</tr>
<tr>
<td style="text-align:left;"><a href="./References.md">Rhee 2014</a></td>
<td style="text-align:left;">Pediatric formulation study in healthy adults</td>
</tr>
<tr>
<td style="text-align:left;"><a href="./References.md">Wenning 2009</a></td>
<td style="text-align:left;">Effect of rifampin on the pharmacokinetics of raltegravir</td>
</tr>
</tbody>
</table>
  </body>
</html>
